NewsBenzinga阿库门制药表示,ALTITUDE-AD 阿尔茨海默病研究未达到主要终点和关键次要终点;公司将停止 Sabirnetug 的临床开发,保留现金并探索战略选择 阿库门制药表示,ALTITUDE-AD 阿尔茨海默病研究未达到主要终点和关键次要终点;公司将停止 Sabirnetug 的临床开发,保留现金并探索战略选择 Benzinga 2026.10.30 11:13 (GMT+0) Open on Benzinga Other news Huobi HTX to Open Spot Trading for SOXS, KORU and SNXX on November 17 Duan Yongping Trims Nvidia and Apple in Q3, Exits Alibaba and CRCL, Opens New SpaceX Stake Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds US Says Justice Leads Megaspeed AI-Chip Investigation Soluna Holdings, Inc. (SLNH) Q3 2026 Earnings Call Transcript ‘The Odds Are Almost Zero’: Scott Galloway Doesn’t See Jensen Huang Returning to Nvidia
Ethereum Glamsterdam upgrade testing finds bug: some internal payments skipped while transaction succeeds